Page last updated: 2024-10-25

clonidine and Parkinsonian Disorders

clonidine has been researched along with Parkinsonian Disorders in 7 studies

Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
"This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD)."9.14The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. ( Fu, Y; Song, C; Wan, Q; Zeng, Y; Zhang, K, 2010)
" Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity."7.74Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008)
"This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD)."5.14The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. ( Fu, Y; Song, C; Wan, Q; Zeng, Y; Zhang, K, 2010)
" Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity."3.74Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008)
" Chronic administration of low doses of the neurotoxin 1-methy,4-phenyl,1,2,3,6-tetrahydropyridine (MPTP) can induce cognitive dysfunction in non-human primates, including impaired performance on a variable delayed response (VDR) task with attentional and memory components."1.36Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism. ( Decamp, E; Schneider, JS; Tinker, JP, 2010)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ostock, CY1
Hallmark, J1
Palumbo, N1
Bhide, N1
Conti, M1
George, JA1
Bishop, C1
Tanabe, M1
Hashimoto, M1
Ono, H1
Schneider, JS1
Tinker, JP1
Decamp, E1
Zhang, K1
Zeng, Y1
Song, C1
Fu, Y1
Wan, Q1
de Rooij, SE1
Jansen, PA1
Samson, MM1
Verhaar, HJ1
Moons, CG1
Archer, T1
Fredriksson, A1
Nash, JR1
Wilson, SJ1
Potokar, JP1
Nutt, DJ1

Trials

1 trial available for clonidine and Parkinsonian Disorders

ArticleYear
The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.
    Journal of neurology, 2010, Volume: 257, Issue:9

    Topics: Aged; Arginine; Clonidine; Diagnosis, Differential; Drug Combinations; Female; Human Growth Hormone;

2010

Other Studies

6 other studies available for clonidine and Parkinsonian Disorders

ArticleYear
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
    Neuropharmacology, 2015, Volume: 95

    Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinso

2015
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
    European journal of pharmacology, 2008, Jul-28, Volume: 589, Issue:1-3

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines

2008
Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism.
    Behavioural brain research, 2010, Aug-25, Volume: 211, Issue:2

    Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Attention; Clonidine; Cognition Disorders;

2010
Growth-hormone release to clonidine and the clinical response to levodopa in parkinsonism.
    Journal of the American Geriatrics Society, 2002, Volume: 50, Issue:9

    Topics: Aged; Antiparkinson Agents; Benserazide; Clonidine; Female; Growth Hormone; Humans; Levodopa; Male;

2002
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
    Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug I

2003
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.
    Neurology, 2003, Oct-28, Volume: 61, Issue:8

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Clonidine; Drug Administration Schedule; Hu

2003